Literature DB >> 10863032

Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis.

M Poloni1, D Facchetti, R Mai, A Micheli, L Agnoletti, G Francolini, G Mora, C Camana, L Mazzini, T Bachetti.   

Abstract

An immunologic pathogenesis for amyotrophic lateral sclerosis (ALS) has been recently proposed. We tested the whole tumour necrosis factor (TNF) system in the serum of 51 ALS patients at different stages of the disease and 36 healthy controls. Antigenic TNF-alpha and its soluble receptors (sTNF-Rs), measured by ELISA, were significantly higher in ALS patients than in healthy controls. However, biologically active TNF-alpha, corresponding to the sTNF-Rs-unbound trimeric TNFalpha molecule and assayed by its cytotoxic activity on a sensitive cell line, was similar between ALS patients and healthy controls. Neither antigenic TNF-alpha, bioactive TNF-alpha nor sTNF-Rs correlated with disease severity, disease duration, or weight loss. In conclusion, we reported an activation of the TNF system in ALS. The role of this activation in the pathogenesis of the disease remains elusive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10863032     DOI: 10.1016/s0304-3940(00)01177-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  62 in total

1.  Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity.

Authors:  Qiang Li; Netanya Y Spencer; Nicholas J Pantazis; John F Engelhardt
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

Review 2.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

Review 3.  Redox modifier genes and pathways in amyotrophic lateral sclerosis.

Authors:  Barrie J Carter; Pervin Anklesaria; Stephanie Choi; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

Review 4.  Glial cells in amyotrophic lateral sclerosis.

Authors:  T Philips; J D Rothstein
Journal:  Exp Neurol       Date:  2014-05-22       Impact factor: 5.330

5.  Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1.

Authors:  Siranush A Sargsyan; Daniel J Blackburn; Siân C Barber; Peter N Monk; Pamela J Shaw
Journal:  Neuroreport       Date:  2009-10-28       Impact factor: 1.837

6.  Neuroprotective effects of estradiol on motoneurons in a model of rat spinal cord embryonic explants.

Authors:  Andrea Cardona-Rossinyol; Margalida Mir; Víctor Caraballo-Miralles; Jerònia Lladó; Gabriel Olmos
Journal:  Cell Mol Neurobiol       Date:  2013-01-16       Impact factor: 5.046

7.  Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients.

Authors:  E F Goodall; M S Haque; K E Morrison
Journal:  J Neurol       Date:  2008-07-18       Impact factor: 4.849

8.  Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models.

Authors:  Eun Jin Yang; Jing Hua Jiang; Sang Min Lee; Sun Choel Yang; Hye Suk Hwang; Myeong Soo Lee; Sun-Mi Choi
Journal:  J Neuroinflammation       Date:  2010-10-15       Impact factor: 8.322

9.  Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.

Authors:  Elijah W Stommel; Jeffrey A Cohen; Camilo E Fadul; Christopher H Cogbill; David J Graber; Linda Kingman; Todd Mackenzie; Jacqueline Y Channon Smith; Brent T Harris
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

10.  Does neuroinflammation fan the flame in neurodegenerative diseases?

Authors:  Tamy C Frank-Cannon; Laura T Alto; Fiona E McAlpine; Malú G Tansey
Journal:  Mol Neurodegener       Date:  2009-11-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.